Coronary atherogenic risk factors in women

European Heart Journal

Volumn 23, Issue 22, 2002, Pages 1738-1752

  Stangl, Verena ^a,b   Baumann, G ^a   Stangl, K ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Schwerpunkt Kardiologie   (Germany)

Author keywords

Atherosclerosis; Coronary heart disease; Female; Gender; Risk factor

Indexed keywords

BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; ESTROGEN; FIBRINOGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; STEROID HORMONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; FAMILY HISTORY; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SEX DIFFERENCE; SOCIAL PSYCHOLOGY;

BLOOD COAGULATION FACTORS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; EXERCISE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIPOPROTEIN(A); MENOPAUSE; OBESITY; PEDIGREE; RISK FACTORS; SMOKING; STRESS, PSYCHOLOGICAL; TRIGLYCERIDES;

EID: 0036847569     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2002.3329     Document Type: Review

References (209)

1. Federal Statistical Office, Germany, Yearbook 2000; 18: 424-5.
2. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996; 124: 518-31.
3. Simons LA. Interrelation of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol 1986; 57: 5G-10G
4. Kuulasmaa K, Tunstall-Pedoe H, Dobson A et al. for the MONICA Project. Estimation of contribution of changes in classic risk factors to trends in coronary event-rates across the WHO MONICA Project populations. Lancet 2000; 355: 675-87.
5. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 Years of follow-up from the Framingham study. JAMA 1987; 257: 2176-80.
6. Keil U. Coronary artery disease: The role of lipids, hypertension and smoking. Basic Res Cardiol 2000; 95: 1/52-1/58.
7. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: The Framingham Heart Study. Can J Cardiol 1988; 4: 5A-10A.
8. Keil U, Liese AD, Hense HW et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J 1998; 19: 1197-207.
9. Maron DJ. The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. Am J Cardiol 2000; 86: 11L-14L.
10. Johnson CL, Rifkind BM, Sempos CT et al. Declining serum total cholesterol levels among US adults: The National Health and Nutrition Examination Surveys. JAMA 1993; 269: 3002-8.
11. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989; 321: 641-6.
12. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90.
13. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989; 79: 8-15.
14. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995; 155: 57-61.
15. Welty FK. Cardiovascular disease and dsylipidemia in women. Arch Intern Med 2001; 161: 514-22.
16. Corti MC, Guralnik JM, Salive ME et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995; 274: 539-44.
17. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332: 1758-66.
18. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988; 62: 1109-12.
19. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women: Review of an NHLBI workshop. Ann Epidemiol 1992; 2: 161-76.
20. Superko HR. Did grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol 1998; 82: 34-46.
21. Superko HR. Lipoprotein subclasses and atherosclerosis. Front Bioscience 2001; 6: 355-65.
22. Reaven GM, Chen YDI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993; 92: 141-6.
23. Kwiterovich PO Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: A current review. Am J Cardiol 2000; 86: 5L-10L.
24. Packard C, Caslake M, Shepherd J. The role of small, dense low density lipoprotein (LDL): A new look. Int J Cardiol 2000; 74: S17-S22.
25. Krauss RM, Blanche PJ. Detection and quantification of LDL subfractions. Curr Opin Lipidol 1992; 3: 377-83.
26. Carr MC, Kim KH, Zambon A et al. Changes in LDL density across the menopausal transition. J Investig Med 2000; 48: 245-50.
27. Anber V, Griffin BA, McConnell M et al. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996; 124: 261-71.
28. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationship of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis 1991; 90: 67-80.
29. Campos H, Genest JJ Jr, Blijlevens E et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992; 12: 187-95.
30. Campos H, Moye LA, Glasser SP, Stampfer MJ, Sacks FM. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA 2001; 286: 1468-74.
31. Ruotolo G, Tettamanti C, Garancini MP et al. Smaller, denser LDL particles are not a risk factor for cardiovascular disease in healthy nonagenarian women of Cremona Population Study. Atherosclerosis 1998; 140: 65-70.
32. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276: 875-81.
33. Stampfer MJ, Krauss RM, Ma J et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-8.
34. Gotto AM Jr. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 22Q-25Q.
35. Gotto AM Jr. Triglyceride. A forgotten risk factor. Circulation 1998; 97: 1027-8.
36. Rubins HB, Robins S, Collins D et al. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341: 410-18.
37. Miller M. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: Further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000; 86: 23L-27L.
38. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992; 70: 733-7.
39. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-36.
40. Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998; 31: 1252-7.
41. Castelli WP. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol 1992; 70: 3H-9H.
42. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-19.
43. Lapidus L, Bengtsson C, Lindquist O, Sigurdsson JA, Ryboe E. Triglycerides - Main lipid risk factor for cardiovascular disease in women? Acta Med Scand 1985; 217: 481-9.
44. D'Agostino RB, Russell MW, Huse DM et al. Primary and subsequent coronary risk appraisal: New results from the Framingham Study. Am Heart J 2000; 139: 272-81.
45. Plow EF, Miles LA. Relationship between plasminogen receptors and Lp(a). In: Scanu AM, ed. Lipoprotein (A). San Diego: Academic Press, 1990: 117-26.
46. Etingin OR, Hajjar DP, Hajjar KA, Harperl PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-I expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991; 266: 2459-65.
47. Scanu AM, Lawn RM, Berg K. Lipoprotein (a) and atherosclerosis. Ann Intern Med 1991; 115: 209-18.
48. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein (a) as a risk factor for ischemic heart disease: Metaanalysis of prospective studies. Clin Chem 1998; 44: 2301-6.
49. Budde T, Fechtrup C, Bösenberg E et al. Plasma Lp(a) levels correlate with number, severity, and length extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 1994; 14: 1730-6.
50. Terres W, Tatsis E, Pfalzer B, Beil U, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation 1995; 91: 948-50.
51. Enas EA. Lipoprotein (a) as a determinant of coronary heart disease in young women: A stronger risk factor than diabetes? Circulation 1998; 97: 293-5.
52. Solymoss BC, Marcil M, Wesolowska E, Gilfix BM, Lespérance, Campeau L. Relation of coronary artery disease in women <60 years of age to the combined elevation of serum lipoprotein (a) and total cholesterol to high-density cholesterol ratio. Am J Cardiol 1993; 72: 1215-19.
53. Orth-Gomer K, Mittleman MA. Schenck-Gustafsson K et al. Lipoprotein (a) as a determinant of coronary heart disease in young women. Circulation 1997; 95: 329-34.
54. Hahmann HW, Schätzer D, Bunte T, Becker D, Schieffer HJ. The significance of high levels of lipoprotein (a) compared with established risk factors in premature coronary artery disease: Differences between men and women. Atherosclerosis 1999; 144: 221-8.
55. Shlipak MG, Simon JA, Vittinghoff E et al. Estrogen and progestin, lipoprotein (a) and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845-52.
56. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutritional Examination Survey, 1988-1991. Hypertension 1995; 25: 305-13.
57. Kannel WB. Risk stratification in hypertension: New insights from the Framingham Study. Am J Hypertens 2000; 13: 3S-10S.
58. Shapiro AP, Rutan GH. Hypertension in women: differences and implications. In: Eaker E, Packard B, Wenger EK et al. eds. Coronary Heart Disease in Women: Proceedings of an NIH Workshop. New York: Haymarket Doyma, 1987: 172-6.
59. Brochier ML, Arwidson P. Coronary heart disease risk factors in women. Eur Heart J (Suppl A) 1998; 19: A45-A52.
60. Corrao JM, Becker RC, Ockene IS, Hamilton GA. Coronary heart disease risk factors in women. Cardiology 1990; 77: 8-12.
61. Nanchahal K, Ashton WD, Wood DA. Association between blood pressure, the treatment of hypertension, and cardiovascular risk factors in women. J Hypertens 2000; 18: 833-41.
62. Hughson WG, Mann JI, Garrod A. Intermittant claudication: prevalence and risk factors. Br J Med 1978; 1: 1379-81.
63. Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GDO, Fowkes FGR. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease. Edingburgh Artery Study. Eur Heart J 1999; 20: 344-53.
64. Doll R, Grey R, Hafner B, Peto R. Mortality in relation to smoking: 20 Years' observation on female British doctors. BMJ 1980; 2: 967-71.
65. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: Evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989; 298: 165-8.
66. Hu FB, Stampfer MJ, Manson JE et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000; 343: 530-7.
67. MMWR Morb Mortal Wkly Rep. Cigarette smoking among adults - United States, 1994 1996; 45: 588-90.
68. Wagenknecht LE, Craven TE, Preisser JS, Manolio TA, Winders S, Hulley SB. Ten-year trends in cigarette smoking among young adults, 1986-1996: The CARDIA Study. Ann Epidemiol 1998; 8: 301-7.
69. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993; 329: 247-56.
70. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000; 343: 16-22.
71. Glantz SA, Parmley WW. Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. Circulation 1991; 83: 1-12.
72. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: An evaluation of the evidence. BMJ 1997; 315: 973-80.
73. Grundy SM, Benjamin IJ, Burke GL et al Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-46.
74. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: A meta-analysis of prospective studies. Diabetes Care 2000; 23: 962-8.
75. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
76. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men. The Rancho Bernardo Study. JAMA 1991; 265: 627-31.
77. Hu FB, Stampfer MJ, Solomon CG et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 Years of follow-up. Arch Intern Med 2001; 161: 1717-23.
78. Laakso M, Ronnemaa T, Lehto S, Puukka P, Kallio V, Pyorala K. Does NIDDM increase the risk for coronary heart disease similarly in both low- and high-risk populations? Diabetologia 1995; 38: 487-93.
79. DERI Study. Sex differences in the mortality associated with insulin-dependent diabetes mellitus in four countries. The Diabetes Epidemiology Research International (DERI) Study. Am J Epidemiol 1991; 133: 577-84.
80. Laing SP, Swerdlow AJ, Slater SD et al. The British Diabetic Association Cohort Study, II: Cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999; 16: 466-71.
81. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report: National Institutes of Health. Obes Res 1998; 6: 51S-209S.
82. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158: 1855-67.
83. Krauss RM, Eckel RH, Howard B et al. AHA Dietary Guidelines: Revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000; 102: 2284-99.
84. Bedinghaus J, Leshan L, Diehr S. Coronary artery disease prevention: What's different for women? Am Fam Physician 2001; 63: 1393-400.
85. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity: Impact on cardiovascular disease. Circulation 1998; 98: 1472-6.
86. Willett WC, Manson JE, Stampfer MJ et al. Weight, weight change, and coronary heart disease in women. JAMA 1995; 273: 461-5.
87. Dorn JM, Schisterman EF, Winkelstein W Jr, Trevisan M. Body mass index and mortality in a general population sample of men and women. The Buffalo Health Study. Am J Epidemiol 1997; 146: 919-31.
88. Schulte H, von Eckardstein A, Cullen P, Assmann G. Obesity and cardiovascular risk. Herz 2001; 26: 170-7.
89. Olson MB, Kelsey SF, Bittner V, et al. Weight cycling and high-density lipoprotein cholesterol in women: Evidence of an adverse effect: a report sponsered from the NHLBI-sponsored WISE study. Women's Ischemia Syndrome Evaluation Study Group. J Am Coll Cardiol 2000; 36: 1565-71.
90. Williams DF. Intentional weight loss: Patterns in the general population and its association with morbidity and mortality. Int J Obes Relat Metab Disord 1997; 21: S14-19.
91. Lissner L, Odell PM, D'Agostino RB et al. Variability of body weight and health outcomes in the Framingham population. N Engl J Med 1991; 324: 1839-44.
92. Vague J. The degree of masculine differentiation of obesities. Am J Clin Nutr 1956; 4: 20-34.
93. Folsum A, Prineas R, Kaye S, Munger R. Incidence of hypertension and stroke in relation to body fat distribution and other risk factors in older women. Stroke 1990; 21: 701-6.
94. Rexrode KM, Carey VJ, Hennekens CH et al Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280: 1843-8.
95. Folsom AR, Kushi LH, Anderson KE et al. Association of general and abdominal obesity with multiple health outcomes in older women: The Iowa Women's Health Study. Arch Intern Med 2000; 160: 2117-28.
96. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-61.
97. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990; 132: 612-28.
98. Lee IM, Rexrode KM, Cook NR, Manson JE, Buring JE. Physical activity and coronary heart disease in women: Is 'no pain, no gain' passé? JAMA 2001; 285: 1447-54.
99. Hu FB, Stampfer MJ, Solomon C et al. Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med 2001; 134: 96-105.
100. Manson JAE, Hu FB, Rich-Edwards JW et al A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med 1999; 341: 650-8.
101. Williams PT. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners. N Engl J Med 1996; 334: 1298-1303.
102. Mayer-Davis EJ, D'Agostino R Jr, Karter AJ et al Intensity and amount of physical activity in relation to insulin sensitivity: The Insulin Resistance Atherosclerosis Study. JAMA 1998; 279: 669-74.
103. Hambrecht R, Wolf A, Gielen S et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000; 17;342: 454-60.
104. Sesso HD, Paffenbarger RS, Ha T, Lee IM. Physical activity and cardiovascular risk in middle-aged and older women. Am J Epidemiol 1999; 150: 408-16.
105. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999; 340: 115-26.
106. Tataru MC, Heinrich J, Junker R et al. C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. Eur Heart J 2000; 21: 1000-8.
107. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo: Assessment by measuring circulating complement-C-reactive protein complexes. J Immunol 1996; 157: 473-9.
108. Torzewski J, Torzewski M, Bowyer DR et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vase Biol 1998; 18: 1386-92.
109. ECAT angina pectoris study. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
110. Kuller LH, Tracy P, Shaten K, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case control study. Am J Epidemiol 1996; 144: 537-47.
111. Ridker PM, Buring JE, Shih H, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
112. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
113. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-44.
114. Lewis SJ, Sacks FM, Mitchell JS et al. for the CARE Investigators. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The cholesterol and recurrent events (CARE) Trial. J Am Coll Cardiol 1998; 32: 140-6.
115. Cushman M, Legault C, Barrett-Connor E et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Intervention (PEPI) study. Circulation 1999; 100: 717-22.
116. The writing group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/ Progestin Interventions (PEPI) trial. JAMA 1995; 273: 199-208.
117. Hulley S, Grady D, Bush T et al. for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
118. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8.
119. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
120. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: Pathogenic mechanisms predisposing to thrombosis. J Nutr 1996; 126: 1285S-1289S.
121. Stangl V, Günther C, Jarrin A et al. Homocysteine inhibits TNF-α induced endothelial adhesion molecule expression and monocyte adhesion via nuclear factor-κB dependent pathway. Biochem Biophys Res Commun 2001; 280: 1093-100.
122. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-9.
123. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SM. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
124. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7.
125. Alfthan G, Pekkanen J, Jauhianen M et al Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis 1994; 106: 9-19.
126. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
127. Folsom AR, Nieto FJ, McGovern PG et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamines: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-10.
128. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risk of cardiovascular disease: Causal or casual. Arch Intern Med 2000; 160: 422-34.
129. Verhoef P. Hyperhomocysteinemia and risk of vascular disease in women. Semin Thromb Hemost 2000; 26: 325-34.
130. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocyst(e)ine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
131. Dierkes J, Jeckel A, Ambrosch A, Westphal S, Luley C, Boeing H. Factors explaining the difference of total homocyst(e)ine between men and women in the European Investigation into Cancer and Nutrition Potsdam Study. Metabolism 2001; 50: 640-5.
132. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH. Homocyst(e)ine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 281: 1817-21.
133. Cortellaro M, Boschetti C, Cofranscesco E et al. The PLAT study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb Vasc Biol 1992; 12: 1063-70.
134. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
135. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen as a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol 1996; 16: 351-6.
136. Thompson SG, Kienast SG, Pyke SDM, Haverkate F, van de Loo JWC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
137. Thompson SG, Fechtrup C, Squire E et al Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996; 16: 357-62.
138. Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: Results from the 8-year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci 1996; 32: 364-70.
139. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res 1993; 70: 1-38.
140. Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischaemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
141. Lee AJ, Fowkes FGR, Lowe GDO, Connor JM, Rumley A. Fibrinogen, Factor VII and PAI-1 genotypes and risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study. Thromb Haemost 1999; 81: 553-60.
142. Meilahn E, Ferrell R, Kiss J et al Genetic determination of coagulation factor VIIc levels among healthy middle-aged women. Thromb Haemost 1995; 73: 623-5.
143. Schenck-Gustafsson K. Risk factors for cardiovascular disease in women: Assessment and management. Eur Heart J 1996; 17 (Suppl D): 2-8.
144. Vasse M, Paysant J, Soria J, Collet JP, Vannier JP, Soria C. Regulation of fibrinogen biosynthesis by cytokines, consequences on the vascular risk. Haemostasis 1996; 26: 331-9.
145. Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998; 19: H11-HI7.
146. Salomaa V, Rasi V, Pekkanen J et al. Haemostatic factors and prevalent coronary heart disease: The FINRISK Haemostasis Study. Eur Heart J 1994; 15: 1293-9.
147. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
148. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. Eur Heart J 1998; 19: 55-62.
149. Eriksson M, Egberg N, Wamala S, Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K. Relationship between plasma fibrinogen and coronary heart disease in women. Arterioscler Thromb Vasc Biol 1999; 19: 67-72.
150. Williams MS, Bray PF. Genetics of arterial prothrombotic risk states. Exp Biol Med 2001; 226: 409-19.
151. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030-4.
152. Ranby M, Sundell IB, Johnson O, Ledin MC, Dahlen G. Activity of plasminogen activator inhibitor-1 (PAI-1) in a population in Northern Sweden. Fibrinolysis 1990; 4: 54-5.
153. Ossei-Gerning N, Wilson IJ, Grant PJ. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. Thromb Haemost 1998; 79: 736-40.
154. Gebara OC, Mittleman MA, Sutherland P et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952-8.
155. Mansfield MW, Heywood DM, Grant PJ. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Res 1996; 16: 160-4.
156. Aznar J, Estelles A, Tormo G et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-41.
157. Thögersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation 1998; 98: 2241-7.
158. Potter van Loon BJ, Kluft K, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type-I is related to insulin resistance. Metabolism 1993; 42: 945-9.
159. Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB. Fibrinogen, factor VII clotting activity and coronary artery severity. Atherosclerosis 1990; 85: 169-73.
160. Suzuki T, Yamauchi K, Matsushita T et al. Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin Cardiol 1991; 14: 731-6.
161. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54-9.
162. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-44.
163. Folsom AR, Wu KK, Rasmussen M, Chambless LE, Aleksic N, Nieto FJ. Determinants of population changes in fibrinogen and factor VII over 6 years. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2000; 20: 601-6.
164. Miller GJ, Stirling Y, Esnouf MP et al. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: An international study. Thromb Haemost 1994; 71: 38-48.
165. Eriksson-Berg M, Silveira A, Orth-Gomer K, Hamsten A, Schenck-Gustafsson K. Coagulation factor VII in middle-aged women with and without coronary heart disease. Thromb Haemost 2001; 85: 787-92.
166. Gensini GF, Comeglio M, Colella A. Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 1998; 19: A53-A61.
167. Gohlke-Bä C. Coronary artery disease - Is menopause a risk factor? Basic Res Cardiol 2000; 95: 1/77-1/83.
168. Oliver MF, Boyd GS. Effect of bilateral ovariectomy on coronary artery disease and serum lipids. Lancet 1959; 2: 690-4.
169. Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of parental history of myocardial infarction and coronary heart disease in women. Am J Epidemiol 1986; 123: 48-58.
170. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61.
171. Van der Schouw YT, van der Graf Y, Steyerberg EW, Eijkemans MJC, Banga JD. Age at natural menopause as a risk factor for cardiovascular mortality. Lancet 1996; 347: 714-18.
172. Dallongeville J, Marecaux N, Isorez D, Zylbergberg G, Fruchart JC, Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995; 118: 123-33.
173. Akahoshi M, Soda M, Nakashima E, Shimaoka K, Seto S, Yano K. Effects of menopause on trends of serum cholesterol, blood pressure and body mass index. Circulation 1996; 94: 61-6.
174. Peters HW, Westendorp IC, Hak AE et al Menopausal status and risk factors for cardiovascular disease. J Intern Med 1999; 246: 521-8.
175. Trémollières FA, Pouilles JM, Cauneille C, Ribot C. Coronary heart disease risk factors and menopause: A study in 1684 French women. Atherosclerosis 1999; 142: 415-23.
176. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM. Haemostatic variables in menopausal status: Influence on hormone replacement therapy. Thromb Haemost 1993; 70: 584-7.
177. Taddei S, Virdis A, Ghiadoni L et al. Menopause is associated with endothelial dysfunction in women. Hypertension 1996; 28: 576-82.
178. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196-204.
179. Gerhard M, Walsh BW, Tawakol A et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998; 98: 1158-63.
180. Koh KK, Cardillo C, Bui MN et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999; 99: 354-60.
181. Collins P, Rosano GM, Sarrel PM et al. 17 Beta-estradiol attenuates acetylcholine-induced coronary arterial constriction in woen but not men with coronary heart disease. Circulation 1995; 92: 24-30.
182. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000; 343: 522-9.
183. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-6.
184. Pastinen T, Perola M, Niini P et al. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Mol Gen 1998; 7: 1453-62.
185. Jukema JW, Kastelein JJ. Tailored therapy to fit individual profiles. Genetics and coronary artery disease. Ann N Y Acad Sci 2000; 902: 17-24.
186. Breslow JL. Genetics of lipoprotein abnormalities associated with coronary heart disease susceptibility. Annu Rev Genet 2000; 34: 233-54.
187. Talmud PJ, Humphries SE. Genetic polymorphisms, lipoproteins and coronary artery disease risk. Curr Opin Lipidol 2001; 12: 405-9.
188. Friedlander Y, Arbogast P, Schwartz SM et al. Family history as a risk factor for early onset myocardial infarction in young women. Atherosclerosis 2001; 156: 201-7.
189. Rissanen AM, Nikkila EA. Coronary artery disease and its risk factors in families of young men with angina pectoris and in controls. Br Heart J 1977; 39: 875-83.
190. Thordarson O, Fridriksson S. Aggregation of deaths from ischaemic heart disease among first-and second degree relatives of 108 males and 42 females with myocardial infarction. Acta Scand Med 1979; 205: 493-500.
191. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. N Engl J Med 1996; 334: 1311-15.
192. Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation 2001; 104: 393-8.
193. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-6.
194. Pastinen T, Perola M, Ignatius J et al. Dissecting a population genome for targeted screening of disease mutations. Hum Mol Genet 2001; 10: 2961-72.
195. Funke H, Assmann G. Strategies for the assessment of genetic coronary artery disease risk. Curr Opin Lipidol 1999; 10: 285-91.
196. Doevendans PA, Jukema W, Spiering W, Defesche JC, Kastelein JJP. Molecular genetics and gene expression in atherosclerosis. Int J Cardiol 2001; 80: 161-72.
197. Frank MB, Reiner AP, Schwartz SM et al. The Kozak sequence polymorphism of platelet glycoprotein Ibalpha and risk of nonfatal myocardial infarction and nonfatal stroke in young women. Blood 2001; 97: 875-9.
198. Ridker PM, Stampfer MJ. Assessment of genetic markers for coronary thrombosis: Promise and precaution. Lancet 1999; 353: 687-8.
199. Karasek RA, Theorell T, Schwartz JE et al. Job characteristics in relation to the prevalence of myocardial infarction in the US Health Examination Survey (HES) and the Health and Nutrition Examination Survey (HANES). Am J Public Health 1988; 78: 910-18.
200. Theorell T, Tsutsumi A, Hallquist J et al. Decision latitude, job strain, and myocardial infarction: A study of working men in Stockholm. The SHEEP Study Group. Stockholm Heart Epidemiology Program. Am J Public Health 1998; 88: 382-8.
201. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implication for therapy. Circulation 1999; 99: 2192-217.
202. Steptoe A, Marmot M. The role of psychobiological pathways in socio-economic inequalities in cardiovascular disease risk. Eur Heart J 2002; 23: 13-25.
203. Eaker ED. Psychosocial risk factors for coronary heart disease in women. Cardiol Clin 1998; 16: 103-11.
204. Orth-Gomer K, Horsten M, Wamala SP et al. Social relations and extent and severity of coronary artery disease: The Stockholm Female Coronary Risk Study. Eur Heart J 1998; 19: 1648-56.
205. Haynes SG, Feinleib M, Kannel WB. The relationship of psychosocial factors to coronary heart disease in the Framingham Study. III. Eight-year incidence of coronary heart disease. Am J Epidemiol 1980; 111: 37-58.
206. MacDougall JM, Dembroski TM, Dimsdale JE, Hackett TP. Components of type A, hostility, and anger-in: Further relationships to angiographic findings. Health Psychol 1985; 4: 137-52.
207. Wamala SP, Mittleman MA, Schenck-Gustafsson K, Orth-Gomer K. Potential explanations of the educational gradient in coronary heart disease: A population based case control study of Swedish women. Am J Public Health 1999; 89: 315-21.
208. Wamala SP, Mittleman MA, Horsten M, Schenck-Gustafsson K, Orth-Gomer K. Job stress and the occupational gradient in coronary heart disease in women: The Stockholm Female Coronary Risk Study. Soc Sci Med 2000; 51: 481-9.
209. Orth-Gomer K, Wamala SP, Horsten M, Schenck-Gustafsson K, Schneiderman N, Mittleman MA. Marital stress worsens prognosis in women with coronary heart disease: The Stockholm Female Coronary Risk Study. JAMA 2000; 284: 3008-14.